SAREPTA THERAPEUTICS, INC. for SAREPTA THERAPEUTICS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
H.R.7389 - MVP Act; All provisions of the bill H.R.7667 - Food and Drug Amendments of 2022; All provisions of the bill H.R.8152 - To provide consumers with foundational data privacy rights, create strong oversight mechanisms, and establish meaningful enforcement; Provisions related to health data S.4348 - FDASLA Act of 2022; All provisions of the bill Issues related to rare disease Issues related to FDA approvals processes Issues related to treatment payment models Prescription Drug User Fee Program Reauthorization; Accelerated Approval
| Lobbyist | Covered position, as disclosed |
|---|---|
| DIANE BERRY | — |
| STACEY FRISK | — |
| CAROLYN HICKEY | — |
| KIP PAYNE New | Senior Legislative Assistant, U.S. House of Representatives |
Taxation/Internal Revenue Code TAX
Tax issues related to research and development
| Lobbyist | Covered position, as disclosed |
|---|---|
| KIP PAYNE New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.